Literature DB >> 7686943

Zymosan-induced tyrosine phosphorylations in human monocytes. Role of protein kinase C.

M V Sanguedolce1, C Capo, M Bouhamdan, P Bongrand, C K Huang, J L Mege.   

Abstract

Protein tyrosine phosphorylations are involved in the proliferation and secretory responses of immune cells, but their role in phagocytes is poorly understood. The ability of unopsonized zymosan to induce protein tyrosine phosphorylations was investigated in human monocytes. The addition of zymosan to monocytes resulted in an increase in tyrosine phosphorylation of several endogenous proteins including 28-, 33-, 38-, 42-, 47-, 55- to 60-, 62-, 68-, 90-, 105-, 116-, and 120-kDa proteins; 55- to 60-kDa proteins were the predominant phosphoproteins. Moreover, we studied the effects of tyrphostin 23, a specific tyrosine kinase inhibitor, on stimulated tyrosine phosphorylations and early secretory responses of monocytes, i.e., arachidonic acid release and oxidative metabolism. We showed that tyrphostin inhibited zymosan-stimulated tyrosine phosphorylations and arachidonic acid release, but that it did not affect superoxide generation induced by zymosan. Zymosan binds mainly to CR3 receptor on human monocytes, and CR3 is devoid of intrinsic tyrosine kinase activity. It was predictable that zymosan stimulated a tyrosine kinase distal to the receptor or associated with it. We observed that PMA mimicked zymosan-induced tyrosine phosphorylations, thus suggesting that both agonists used a common transductional pathway implicating the serine/threonine kinase, protein kinase C. The antagonists of protein kinase C, sphingosine and calphostin C, inhibited zymosan-stimulated tyrosine phosphorylations. We suggest that, in human monocytes, zymosan-induced tyrosine phosphorylations are involved in cell responses such as the release of arachidonic acid, and that they require the sequential activation of protein kinase C and cellular protein tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686943

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Receptor-mediated phagocytosis of myelin by macrophages and microglia: effect of opsonization and receptor blocking agents.

Authors:  K Mosley; M L Cuzner
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

3.  The role of tyrosine phosphorylation in lipopolysaccharide- and zymosan-induced procoagulant activity and tissue factor expression in macrophages.

Authors:  A P Dackiw; S Grinstein; G F Brisseau; I D McGilvray; A B Nathens; J A McGuire; R Romanek; P Y Cheung; O D Rotstein
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Role of CR4 in Mycobacterium tuberculosis-human macrophages binding and signal transduction in the absence of serum.

Authors:  Y Zaffran; L Zhang; J J Ellner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Induction of macrophage procoagulant activity by murine hepatitis virus strain 3: role of tyrosine phosphorylation.

Authors:  A P Dackiw; K Zakrzewski; A B Nathens; P Y Cheung; R Fingerote; G A Levy; O D Rotstein
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Enhanced generation of reactive oxygen species in monocytes from patients with common variable immunodeficiency.

Authors:  P Aukrust; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

7.  Inhibition by sphingosine of leukemic cell killing by human monocytes activated with interleukin-2: a possible role of protein kinase C.

Authors:  Y Nakabo; M J Pabst
Journal:  Jpn J Cancer Res       Date:  1998-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.